- Home
- DMAC vs USCB Comparison
DMAC vs USCB Comparison
Compare DMAC & USCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- USCB
- Stock Information
- Founded
- DMAC 2000
- USCB 2002
- Country
- DMAC United States
- USCB United States
- Employees
- DMAC N/A
- USCB N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- USCB Major Banks
- Sector
- DMAC Health Care
- USCB Finance
- Exchange
- DMAC Nasdaq
- USCB Nasdaq
- Market Cap
- DMAC 310.1M
- USCB 316.4M
- IPO Year
- DMAC N/A
- USCB 2021
- Fundamental
- Price
- DMAC $6.97
- USCB $17.30
- Analyst Decision
- DMAC Strong Buy
- USCB Strong Buy
- Analyst Count
- DMAC 3
- USCB 3
- Target Price
- DMAC $12.33
- USCB $22.00
- AVG Volume (30 Days)
- DMAC 443.2K
- USCB 20.0K
- Earning Date
- DMAC 11-12-2025
- USCB 10-30-2025
- Dividend Yield
- DMAC N/A
- USCB 2.32%
- EPS Growth
- DMAC N/A
- USCB 67.08
- EPS
- DMAC N/A
- USCB 1.47
- Revenue
- DMAC N/A
- USCB $88,094,000.00
- Revenue This Year
- DMAC N/A
- USCB $25.60
- Revenue Next Year
- DMAC N/A
- USCB $5.04
- P/E Ratio
- DMAC N/A
- USCB $11.71
- Revenue Growth
- DMAC N/A
- USCB 32.06
- 52 Week Low
- DMAC $3.19
- USCB $13.90
- 52 Week High
- DMAC $7.49
- USCB $21.86
- Technical
- Relative Strength Index (RSI)
- DMAC 66.23
- USCB 51.29
- Support Level
- DMAC $6.83
- USCB $17.16
- Resistance Level
- DMAC $7.41
- USCB $17.45
- Average True Range (ATR)
- DMAC 0.42
- USCB 0.46
- MACD
- DMAC 0.06
- USCB -0.01
- Stochastic Oscillator
- DMAC 77.88
- USCB 33.95
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.